MetroWest Business Digest for Sept. 7, 2017

Thursday

Sep 7, 2017 at 3:01 AM

Barre3 to open Sudbury location

Barre3, of Sudbury, a network of studios that promote the ballet barre fitness movement, will open its newest location on Sept. 14 in the Mill Village Center, 365 Boston Post Road. To celebrate the studio opening, owner Natasha Groblewski will offer free classes and free Kid’s Play Lounge during the first weekend. Barre3 Sudbury will be partnering with local businesses to raffle prizes and gifts. Continuing, for a limited time, Barre3 will offer its specially priced Founding Membership option for the unlimited monthly membership. Ongoing, Barre3 Sudbury will offer a class schedule seven days a week as early as 6 a.m. and as late 7 p.m. with the Kid’s Play Lounge available during many classes each week. Created by fitness expert Sadie Lincoln, Barre3 offers a whole-body health approach to wellness with workouts rooted in three fitness disciplines — ballet barre, Pilates and yoga. For information: sudbury@barre3.com.

Profitect CEO announces presentation

Profitect, of Waltham, the leading prescriptive analytics provider for the retail and CPG industries, announced that company CEO Guy Yehiav will speak on prescriptive analytics and the successes seen at Profitect at the Goldman Sachs 24th annual Global Retailing Conference at 3:55 p.m. Sept. 6. Yehiav will participate in a panel session on emerging technology solutions for retail. Profitect is only one of a select few technology companies attending the exclusive conference taking place in New York City Sept. 6 and 7 at The Plaza Hotel.

Minerva Neuroscience announces first patient enrollment

Minerva Neurosciences, of Waltham, a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, recently announced the enrollment of the first patient in a phase 2b clinical trial of seltorexant (MIN-202) as adjunctive therapy to antidepressants in adult patients with major depressive disorder who have responded inadequately to antidepressant therapy.

Radius Health announces presentation

Radius Health, of Waltham, a science-driven biopharmaceutical company committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases recently announced that the abstract titled “Sustained Fracture Risk Reduction with Sequential Abaloparatide/Alendronate: Results of ACTIVExtend,” will be presented in an Oral Plenary Session at the ASBMR 2017 annual meeting. The 43-month results of ACTIVE and ACTIVExtend provide new insights into a treatment paradigm using TYMLOS, an anabolic agent, followed by alendronate, an antiresorptive. Radius will also present seven posters highlighting pre-clinical and clinical data for TYMLOS (abaloparatide) at the Congress in Denver, Colorado. TYMLOS was approved by the U.S. Food and Drug Administration on April 28, for the treatment of postmenopausal women with osteoporosis at high risk for fracture and has demonstrated significant reductions in the risk of new vertebral and nonvertebral fractures.

Market Place

Original content available for non-commercial use under a Creative Commons license, except where noted.
MetroWest Daily News, Framingham, MA ~ 33 New York Ave., Framingham, MA 01701 ~ Privacy Policy ~ Terms Of Service